Personalis, Inc. (PSNL) stock
PSNLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/30345% above fair value
$14.98+0.18 (+1.22%)
Close on Nov 18, 2026Market cap $1.60BP/E –Yield –
Personalis operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Personalis's operating income for the twelve months ending Jun 30, 2026 was -$114.31M. For fiscal 2025 it was -$88.06M. The highest annual figure on record is -$13.77M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$88.06M | – |
| FY2024 | Dec 31, 2024 | -$68.27M | – |
| FY2023 | Dec 31, 2023 | -$109.94M | – |
| FY2022 | Dec 31, 2022 | -$115.53M | – |
| FY2021 | Dec 31, 2021 | -$65.35M | – |
| FY2020 | Dec 31, 2020 | -$42.15M | – |
| FY2019 | Dec 31, 2019 | -$22.42M | – |
| FY2018 | Dec 31, 2018 | -$13.77M | – |
| FY2017 | Dec 31, 2017 | -$22.16M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$33.59M | – |
| Q1 FY2026 | Mar 31, 2026 | -$32.16M | – |
| Q4 FY2025 | Dec 31, 2025 | -$25.27M | – |
| Q3 FY2025 | Sep 30, 2025 | -$23.29M | – |
| Q2 FY2025 | Jun 30, 2025 | -$21.80M | – |
| Q1 FY2025 | Mar 31, 2025 | -$17.70M | – |
| Q4 FY2024 | Dec 31, 2024 | -$18.11M | – |
| Q3 FY2024 | Sep 30, 2024 | -$14.38M | – |
| Q2 FY2024 | Jun 30, 2024 | -$16.89M | – |
| Q1 FY2024 | Mar 31, 2024 | -$18.88M | – |
| Q4 FY2023 | Dec 31, 2023 | -$23.97M | – |
| Q3 FY2023 | Sep 30, 2023 | -$30.79M | – |
| Q2 FY2023 | Jun 30, 2023 | -$25.35M | – |
| Q1 FY2023 | Mar 31, 2023 | -$29.83M | – |
| Q4 FY2022 | Dec 31, 2022 | -$32.09M | – |
| Q3 FY2022 | Sep 30, 2022 | -$27.26M | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.88M | – |
| Q1 FY2022 | Mar 31, 2022 | -$28.31M | – |
| Q4 FY2021 | Dec 31, 2021 | -$20.23M | – |
| Q3 FY2021 | Sep 30, 2021 | -$17.69M | – |
| Q2 FY2021 | Jun 30, 2021 | -$14.95M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.49M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.37M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.65M | – |
| Q2 FY2020 | Jun 30, 2020 | -$9.50M | – |
| Q1 FY2020 | Mar 31, 2020 | -$9.63M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.20M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.73M | – |
| Q2 FY2019 | Jun 30, 2019 | -$4.06M | – |
| Q1 FY2019 | Mar 31, 2019 | -$5.43M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.15M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.75M | – |
| Q2 FY2018 | Jun 30, 2018 | -$3.71M | – |
See a number that looks wrong?